(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of -8.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.91%.
Cormedix's revenue in 2026 is $462,248,553.On average, 7 Wall Street analysts forecast CRMD's revenue for 2026 to be $26,799,596,921, with the lowest CRMD revenue forecast at $25,586,003,796, and the highest CRMD revenue forecast at $28,153,489,829. On average, 7 Wall Street analysts forecast CRMD's revenue for 2027 to be $22,773,772,586, with the lowest CRMD revenue forecast at $21,571,091,667, and the highest CRMD revenue forecast at $23,988,145,154.
In 2028, CRMD is forecast to generate $27,455,888,129 in revenue, with the lowest revenue forecast at $24,955,434,215 and the highest revenue forecast at $29,978,945,897.